OTCPK:LIFS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Life Stem Genetics Inc., a development stage company, focuses on establishing stem cell therapy based clinics worldwide. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Life Stem Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LIFS has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

LIFS

1.3%

US Healthcare

1.3%

US Market


1 Year Return

9,900.0%

LIFS

21.2%

US Healthcare

15.8%

US Market

Return vs Industry: LIFS exceeded the US Healthcare industry which returned 21% over the past year.

Return vs Market: LIFS exceeded the US Market which returned 13.8% over the past year.


Shareholder returns

LIFSIndustryMarket
7 Day0%1.3%1.3%
30 Day0%-4.3%-4.1%
90 Day0%-0.7%8.4%
1 Year9,900.0%9,900.0%22.8%21.2%18.4%15.8%
3 Year-66.7%-66.7%23.8%18.5%38.2%29.0%
5 Year-85.7%-85.7%50.2%39.6%84.9%64.0%

Price Volatility Vs. Market

How volatile is Life Stem Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Life Stem Genetics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Life Stem Genetics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Life Stem Genetics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Life Stem Genetics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Life Stem Genetics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Life Stem Genetics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Life Stem Genetics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Life Stem Genetics performed over the past 5 years?

8.7%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Life Stem Genetics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • Examine Life Stem Genetics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Life Stem Genetics's filings and announcements here.
  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is Life Stem Genetics's financial position?


In this section we usually analyse Life Stem Genetics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Life Stem Genetics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of LIFS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Life Stem Genetics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Life Stem Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LIFS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LIFS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LIFS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LIFS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LIFS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Gloria Simov (34 yo)

7.08yrs

Tenure

US$5,000

Compensation

Ms. Gloria Simov has been Chief Executive Officer and President of Life Stem Genetics, Inc. since August 26, 2013. As well as carrying out her executive functions, Ms. Simov is responsible for development ...


Leadership Team

NamePositionTenureCompensationOwnership
Gloria Simov
CEO, President & Director7.08yrsUS$5.00kno data
Heather Sharp
Chief Financial Officerno datano datano data
Vino Padayachee
Chairman & Business Development Director6.5yrsno datano data
James Bosch
Chief Medical Stem Cell Specialist6.75yrsno datano data

6.8yrs

Average Tenure

48yo

Average Age

Experienced Management: LIFS's management team is seasoned and experienced (6.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gloria Simov
CEO, President & Director7.08yrsUS$5.00kno data
Heather Sharp
Chief Financial Officerno datano datano data
Vino Padayachee
Chairman & Business Development Director6.5yrsno datano data
Roberto Viña
Member of Medical Advisory Board6.42yrsno datano data
Matthew Sullivan
Member of Executive Advisory Board6.92yrsno datano data
David Granovsky
Corporate Advisorno datano datano data
Shahab Bakhtyar
Member of Executive Advisory Board6.92yrsno datano data
Shirin Rostamkalaee
Member of Executive Advisory Board6.83yrsno datano data
Ranbir Gill
Member of Medical Advisory Board6.42yrsno datano data
Praveen Gill
Member of Medical Advisory Board6.42yrsno datano data

6.7yrs

Average Tenure

48yo

Average Age

Experienced Board: LIFS's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Life Stem Genetics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Life Stem Genetics Inc.
  • Ticker: LIFS
  • Exchange: OTCPK
  • Founded: 2012
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$4.583k
  • Shares outstanding: 45.84m

Location

  • Life Stem Genetics Inc.
  • 433 North Camden Drive
  • Suite 400
  • Beverly Hills
  • California
  • 90210
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LIFSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2013

Biography

Life Stem Genetics Inc., a development stage company, focuses on establishing stem cell therapy based clinics worldwide. Its products and services include nutraceutical and medical supplements, and IV nutr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/29 00:33
End of Day Share Price2020/09/28 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.